Key result
GLP-1 agonists maintain ~102% greater microvascular dilation versus doxorubicin alone in isolated human arterioles.
Why the study?
Chemotherapy agents such as doxorubicin increase MACE risk, and GLP-1 receptor agonists may reduce MACE in cancer survivors, prompting investigation into their potential to protect against or rescue impaired microvascular vasodilation following doxorubicin exposure.
Do GLP-1 receptor agonists preserve microvascular endothelial function following doxorubicin exposure in isolated human arterioles?
Do GLP-1 receptor agonists preserve microvascular endothelial function following doxorubicin exposure in isolated human arterioles?
GLP-1 receptor agonists preserve microvascular endothelial function against doxorubicin-induced damage in isolated human arterioles, suggesting a potential cardioprotective role in chemotherapy.
Answers are grounded in this paper and cite their sources.
Liraglutide preserves microvascular dilation during doxorubicin exposure in animal arterioles; leaves open translation to cardioprotection in human chemotherapy.
Introduction: Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) have become a common treatment for patients with type 2 diabetes (T2D) and obesity. Numerous clinical trials in patients with T2D treated with GLP1 RAs have demonstrated a reduction in major adverse cardiovascular events (MACE), providing evidence of cardioprotective effects of GLP-1 RAs. Chemotherapy agents (CTx), such as doxorubicin (Dox), significantly increase the risk of MACE and a recent retrospective study suggests GLP-1 RAs may reduce risk of MACE in cancer survivors. With this background, we hypothesized that GLP-1 RAs would provide a protective or rescue effect to impaired microvascular vasodilation following exposure to Dox.Methods: Fresh human adipose tissues were obtained as de-identified surgical discarded specimens. Arterioles (100-150 µm) were cannulated and examined flow-mediated dilation (FMD, measured at steady‐state during varying intraluminal pressure gradients (5-100 cmH2O)) using video microscopy. Protocol I: Arterioles were dissected from subjects with ≤2 cardiovascular risk factors (CTRL) or T2D and were incubated in a culture media at 37°C for 16-20 hours with Dox (100 nM), liraglutide (10 nM), or combination of both. Protocol II: Arterioles were dissected from subjects being clinically treated with (~10 days prior to tissue collection) semaglutide or tirzepatide. Isolated vessels were incubated in a culture media at 37°C for 16-20 hours with Dox (100 nM). Data are presented as %max. dilation at 100 cmH2O and compared using two-way repeated measures ANOVA. Results: Protocol I: Vasodilation was significantly impaired in vessels from T2D patients compared to CTRL (70±7% in T2D vs. 97±1% in CTRL, n=6, P< 0.05). In contrast, the dilation was significantly improved in T2D vessels treated with GLP-1 RA liraglutide (88±4% in liraglutide, n=6, P=0.445). Exposure to Dox significantly reduced vasodilation in CTRL arterioles (44±5% in Dox, n=7, P< 0.001), while combination of Dox and liraglutide preserved dilatory capacity (89±9% in liraglutide + Dox, n=7, P< 0.001). Protocol II: Exposure to Dox did not affect arterioles isolated from subjects on GLP-1 RAs (semaglutide; 90±5% in Dox vs. 89±5% in control, n=7, P< 0.001, tirzepatide; 86±3% in Dox vs. 93±2% in control, n=8, P< 0.001). Smooth muscle dependent dilation to papaverine (100 µM) was not changed in all groups.Conclusion: GLP-1 RAs significantly improved vasodilation in isolated human arterioles from T2D subjects and suggest a protective effect against CTx-induced microvascular dysfunction. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
No takes yet. Share an insight, caveat, or question.
Nishijima et al. (2026) studied Type 2 diabetes and chemotherapy-induced vascular damage. GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) vs. Untreated or doxorubicin alone was evaluated on Flow-mediated dilation (%max. dilation at 100 cmH2O) (p=<0.001). GLP-1 receptor agonists preserved microvascular dilatory capacity against doxorubicin-induced dysfunction in isolated human arterioles.
Synapse has enriched 10 related papers. Consider them for comparative context: